Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP2 | Q9UGN5 | 11/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.59 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.59 |
| ▸ | TNKS | O95271 | 2/20 | 0.59 |
| ▸ | PARP1 | P09874 | 2/20 | 0.59 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.59 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.59 |
| ▸ | PARP16 | Q8N5Y8 | 2/20 | 0.59 |
| ▸ | PARP12 | Q9H0J9 | 2/20 | 0.59 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.59 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.59 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25323275 | 0.80 | PARP10 (0.66) | PARP2PARP10PARP15TNKS2TNKS | |
| SCHEMBL25323961 | 0.74 | PARP10 (1.00) | PARP2PARP10PARP15TNKS2TNKS | |
| SCHEMBL25324810 | 0.71 | PARP2 (0.67) | PARP2PARP10PARP15TNKS2TNKS | |
| SCHEMBL25323659 | 0.71 | PARP2 (0.67) | PARP2PARP10PARP15TNKS2TNKS | |
| SCHEMBL25322731 | 0.69 | PARP2 (1.00) | PARP2PARP10PARP15TNKS2TNKS | |
| Bromide SCHEMBL11743370 | 0.68 | CHEK1 (0.96) | PARP2PARP10PARP15TNKS2TNKS | |
| SCHEMBL25323671 | 0.64 | PARP2 (0.56) | PARP2PARP10PARP15TNKS2TNKS | |
| SCHEMBL4615700 | 0.62 | NPSR1 (0.47) | TP53MAPTHPGDGAASMN1; SMN2 | |
| SCHEMBL4615704 | 0.62 | NPSR1 (0.47) | TP53MAPTHPGDGAASMN1; SMN2 | |
| SCHEMBL11533095 | 0.61 | PARP10 (0.57) | PARP2PARP10PARP15TNKS2TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177359-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2025-06-05 | — | — | US | disclosed |
| EP-4469046-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | Oulun Yliopisto (FI) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144450-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144450-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | OULUN YLIOPISTO (FI) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177359-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | NAMPT, NADK, NQO1 | PARP2 15/4885PARP10 11/4885PARP15 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.